Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Organisation › Details

Immatics US Inc.

Immatics US, Inc. was launched by Immatics and MDACC to develop multiple next-generation adoptive cellular therapies for the treatment of cancer. Immatics US, Inc. is well positioned to become the global leader in ACT based on Immatics’ unrivaled cancer target discovery capabilities, which allow it to access all types of cellular cancer targets including intracellular targets currently not addressed by other ACT approaches. Immatics US, Inc. will focus on three adoptive cell therapy development approaches to treat tumors based on the significant expertise of leading academic collaborators: ACTolog™, ACTengine™ and ACTallo™. ACTolog™ involves selecting, enriching and the ex-vivo expansion of a patient’s endogenous T cells specifically recognizing Immatics’ XPRESIDENT® targets. The ACTolog approach is based on the work of Cassian Yee, M.D., Professor of Medical Melanoma Oncology at MD Anderson. ACTengine™ involves genetically engineering a patient’s own T cells to express novel T-cell receptors which are specific to Immatics’ XPRESIDENT® targets. ACTallo™ is an allogenic approach that will use off-the-shelf T cells that have been engineered to express novel T-cell receptors. The first ACTolog™, ACTengine™ and ACTallo™ clinical candidates, targeting cancers with high medical need, are expected to enter the clinic in 2016. Immatics US, Inc. has been awarded a $19.7 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). It has also received a commitment for over $40 million of funding from the parent company, Immatics Biotechnologies GmbH. MD Anderson is a shareholder of Immatics US, Inc. Immatics US, Inc. is led by Harpreet Singh (Chief Executive Officer), Steffen Walter (Chief Scientific Officer), Toni Weinschenk (Chief Technology Officer) and Carsten Reinhardt (Chief Medical Officer). Immatics US, Inc. is based in Houston, Texas. *

 

Period Start 2015-08-26 established jv
  Group Immatics (Group)
Products Industry adoptive cellular therapy (ACT)
  Industry 2 TCR engineered T-cells
Persons Person Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
  Person 2 Reinhardt, Carsten (Immatics 200910– CMO before Micromet 200506– CMO before Roche)
     
Region Region Houston, TX
  Country United States (USA)
  City n. a. Houston, TX
    Address record changed: 2015-09-19
     
Basic data Employees n. a.
     
    * Document for �About Section�: Immatics Biotechnologies GmbH. (8/26/15). "Press Release: Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies. Immatics US, Inc. Has Secured over $60m in Total Funding". Tübi
     
   
Record changed: 2019-07-13

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

More documents for Immatics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top